यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

omega pharma ltd - nicotine - medicated chewing-gum - 4mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - amorolfine hydrochloride - medicated nail lacquer - 50mg/1ml

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: crospovidone; pregelatinised maize starch; povidone; purified water; microcrystalline cellulose; magnesium stearate; stearic acid - temporary relief of the following cold and flu symptoms: nasal congestion, sinus pain, runny nose, headache and body aches & pains. reduces fever

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

omega pharma ltd - nicotine - medicated chewing-gum - 2mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

omega pharma ltd - nicotine - medicated chewing-gum - 4mg

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - lidocaine - medicated plaster - 700 milligram(s) - amides; lidocaine

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - lidocaine - medicated plaster - 700 milligram(s) - amides; lidocaine

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - lidocaine - medicated plaster - 700 milligram(s) - amides; lidocaine

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

st. mary's medical park pharmacy - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium tablets are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. warfarin sodium is contraindicated in: - pregnancy warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

st. mary's medical park pharmacy - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology —clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequately studie